David L. Corcoran

David L. Corcoran

Auto-generated profile, based on publicly available information

David L. Corcoran

University of North Carolina at Chapel Hill

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2012 in Nature
Verified
Journal Article
Open access
PDF file
MAManuel Ascano
Manuel Ascano
NMNeelanjan Mukherjee
Neelanjan Mukherjee
PBPradeep Bandaru
Pradeep Bandaru
JMJason B. Miller
Jason B. Miller
JNJeffrey D. Nusbaum
Jeffrey D. Nusbaum
TTThomas Tuschl
Thomas Tuschl
Fragile X syndrome (FXS) is a multi-organ disease that leads to mental retardation, macro-orchidism in males and premature ovarian insufficiency in female carriers. FXS is also a prominent monogenic disease associated with autism spectrum disorders (ASDs). FXS is typically caused by the loss of fragile X mental retardation 1 (FMR1) expression, which codes for the RNA-binding protein FMRP. Here we report the discovery of distinct RNA-recognition elements that correspond to the two independent RNA-binding domains of FMRP, in addition to the binding sites within the messenger RNA targets for wild-type and I304N mutant FMRP isoforms and the FMRP paralogues FXR1P and FXR2P (also known as FXR1 and FXR2). RNA-recognition-element frequency, ratio and distribution determine target mRNA association with FMRP. Among highly enriched targets, we identify many genes involved in ASD and show that FMRP affects their protein levels in human cell culture, mouse ovaries and human brain. Notably, we discovered that these targets are also dysregulated in Fmr1−/− mouse ovaries showing signs of premature follicular overdevelopment. These results indicate that FMRP targets share signalling pathways across different cellular contexts. As the importance of signalling pathways in both FXS and ASD is becoming increasingly apparent, our results provide a ranked list of genes as basis for the pursuit of new therapeutic targets for these neurological disorders.

1 August 2011 in Molecular Cell
Verified
Journal Article
Closed access
NMNeelanjan Mukherjee
Neelanjan Mukherjee
DCDavid L. Corcoran
David L. Corcoran
JNJeffrey D. Nusbaum
Jeffrey D. Nusbaum
DRDavid W. Reid
David W. Reid
SGStoyan Georgiev
Stoyan Georgiev
JKJack D. Keene
Jack D. Keene

6 September 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JMJosine L. Min
Josine L. Min
GHGibran Hemani
Gibran Hemani
EHEilis Hannon
Eilis Hannon
KDKoen F. Dekkers
Koen F. Dekkers
JCJuan Castillo-Fernandez
Juan Castillo-Fernandez
CRCaroline L. Relton
Caroline L. Relton

15 July 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
KPKusum V. Pandit
Kusum V. Pandit
DCDavid Corcoran
David Corcoran
HYHanadie Yousef
Hanadie Yousef
MYManohar Yarlagadda
Manohar Yarlagadda
ATArgyris Tzouvelekis
Argyris Tzouvelekis
NKNaftali Kaminski
Naftali Kaminski
Rationale: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and usually lethal fibrotic lung disease characterized by profound changes in epithelial cell phenotype and fibroblast proliferation. Objectives: To determine changes in expression and role of microRNAs in IPF. Methods: RNA from 10 control and 10 IPF tissues was hybridized on Agilent microRNA microarrays and results were confirmed by quantitative real-time polymerase chain reaction and in situ hybridization. SMAD3 binding to the let-7d promoter was confirmed by chromatin immunoprecipitation, electrophoretic mobility shift assay, luciferase assays, and reduced expression of let-7d in response to transforming growth factor-β. HMGA2, a let-7d target, was localized by immunohistochemistry. In mice, let-7d was inhibited by intratracheal administration of a let-7d antagomir and its effects were determined by immunohistochemistry, immunofluorescence, quantitative real-time polymerase chain reaction, and morphometry. Measurements and Main Results: Eighteen microRNAs including let-7d were significantly decreased in IPF. Transforming growth factor-β down-regulated let-7d expression, and SMAD3 binding to the let-7d promoter was demonstrated. Inhibition of let-7d caused increases in mesenchymal markers N-cadherin-2, vimentin, and α-smooth muscle actin (ACTA2) as well as HMGA2 in multiple epithelial cell lines. let-7d was significantly reduced in IPF lungs and the number of epithelial cells expressing let-7d correlated with pulmonary functions. HMGA2 was increased in alveolar epithelial cells of IPF lungs. let-7d inhibition in vivo caused alveolar septal thickening and increases in collagen, ACTA2, and S100A4 expression in SFTPC (pulmonary-associated surfactant protein C) expressing alveolar epithelial cells. Conclusions: Our results indicate a role for microRNAs in IPF. The down-regulation of let-7d in IPF and the profibrotic effects of this down-regulation in vitro and in vivo suggest a key regulatory role for this microRNA in preventing lung fibrosis. Clinical trial registered with www.clinicaltrials.gov (NCT 00258544).

8 December 2010 in Nature
Verified
Journal Article
Closed access
AKAlex T. Kalinka
Alex T. Kalinka
KVKarolina M. Varga
Karolina M. Varga
DGDave T. Gerrard
Dave T. Gerrard
SPStephan Preibisch
Stephan Preibisch
DCDavid L. Corcoran
David L. Corcoran
PTPavel Tomancak
Pavel Tomancak

18 August 2011 in Genome Biology
Verified
Journal Article
Open access
PDF file
DCDavid L Corcoran
David L Corcoran
SGStoyan Georgiev
Stoyan Georgiev
NMNeelanjan Mukherjee
Neelanjan Mukherjee
EGEva Gottwein
Eva Gottwein
RSRebecca L Skalsky
Rebecca L Skalsky
UOUwe Ohler
Uwe Ohler
Crosslinking and immunoprecipitation (CLIP) protocols have made it possible to identify transcriptome-wide RNA-protein interaction sites. In particular, PAR-CLIP utilizes a photoactivatable nucleoside for more efficient crosslinking. We present an approach, centered on the novel PARalyzer tool, for mapping high-confidence sites from PAR-CLIP deep-sequencing data. We show that PARalyzer delineates sites with a high signal-to-noise ratio. Motif finding identifies the sequence preferences of RNA-binding proteins, as well as seed-matches for highly expressed microRNAs when profiling Argonaute proteins. Our study describes tailored analytical methods and provides guidelines for future efforts to utilize high-throughput sequencing in RNA biology. PARalyzer is available at http://www.genome.duke.edu/labs/ohler/research/PARalyzer/.